{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:05:13Z","timestamp":1759665913814},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":669,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/jto.0b013e3182a7d22e","type":"journal-article","created":{"date-parts":[[2014,1,14]],"date-time":"2014-01-14T04:34:05Z","timestamp":1389674045000},"page":"e12-e16","source":"Crossref","is-referenced-by-count":19,"title":["Stabilization of Disease after Targeted Therapy in a Thymic Carcinoma with KIT Mutation Detected by Clinical Next-Generation Sequencing"],"prefix":"10.1016","volume":"9","author":[{"given":"Ian S.","family":"Hagemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramaswamy","family":"Govindan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cylen","family":"Javidan-Nejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine E.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3182a7d22e_bib1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ncponc1251","article-title":"Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib","volume":"5","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib3","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase","volume":"279","author":"Mol","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib4","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/157488707781662689","article-title":"Systemic therapeutic options in thymic malignancies: a glimmer of hope","volume":"2","author":"Hammond-Thelin","year":"2007","journal-title":"Rev Recent Clin Trials"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib6","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ctrv.2012.11.005","article-title":"Thymoma and thymic carcinoma in the target therapies era","volume":"39","author":"Lamarca","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2045-3329-2-16","article-title":"Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications","volume":"2","author":"Postow","year":"2012","journal-title":"Clin Sarcoma Res"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib9","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/jso.21930","article-title":"Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options","volume":"104","author":"Caram","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib10","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1093\/annonc\/mdr626","article-title":"Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors","volume":"23","author":"Schirosi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejca.2003.11.025","article-title":"Use of c-KIT\/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group","volume":"40","author":"Debiec-Rychter","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ijc.23137","article-title":"Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor","volume":"122","author":"Kleinbaum","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib13","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2010.09.011","article-title":"Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation","volume":"71","author":"Di\u015fel","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1378\/chest.128.1.140","article-title":"Immunohistochemical KIT (CD117) expression in thymic epithelial tumors","volume":"128","author":"Nakagawa","year":"2005","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib16","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10 Suppl 4","key":"10.1097\/JTO.0b013e3182a7d22e_bib17","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1097\/JTO.0b013e3181f209b9","article-title":"Thymic tumors: relevant molecular data in the clinic","volume":"5","author":"Girard","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib18","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/1078-0432.CCR-04-2515","article-title":"Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling","volume":"11","author":"Tarn","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib19","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1200\/JCO.2011.36.6427","article-title":"Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma","volume":"29","author":"Buti","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lungcan.2013.01.003","article-title":"When a thymic carcinoma \u201cbecomes\u201d a GIST","volume":"80","author":"Rossi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib21","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Str\u00f6bel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43\u20139006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thoracic Oncol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib25","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling","volume":"18","author":"Guex","year":"1997","journal-title":"Electrophoresis"},{"key":"10.1097\/JTO.0b013e3182a7d22e_bib26","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415302008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415302008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T10:23:13Z","timestamp":1538907793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415302008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1556086415302008"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3182a7d22e","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}